Cagrilintide and tesamorelin have meaningful human data in other settings
Peptides Sold by Swiss Chems Swiss Chems carries numerous research peptides, primarily in lyophilized powder form
It does not raise testosterone, growth hormone, or IGF-1 directly
Musculoskeletal diseases: Mechanisms and therapeutic advances
NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage
GHK-Cu is not approved or licensed by the MHRA as a treatment for hair loss in the UK, and it is not included in NICE or NHS guidance